Skip to main content
NCD 190.29 · version 1 · Laboratory NCD

NCD 190.29: Tumor Antigen by Immunoassay - CA 15-3/CA 27.29

Reviewed by QuickIntell RCM Editorial Team · Last reviewed

Data effective
Data currency: Medicare Coverage Database release of September 24, 2026 (effective September 20, 2026); Lab NCD code lists January 2026 (effective January 1, 2026). Next CMS release: weekly (every Thursday) for the MCD; quarterly for lab NCD code lists.

Key facts for NCD 190.29

Benefit category
Diagnostic Laboratory Tests
Effective date
11/25/2002
Implemented 01/01/2003
Transmittal
Transmittal 17
Versions published
1
Manual chapter
190
NCD Manual (Pub. 100-03)
Lab edit list
71 covered ICD-10
245 non-covered

TL;DR

NCD 190.29 sets Medicare's national policy for tumor antigen by immunoassay - ca 15-3/ca 27.29 under the benefit category "Diagnostic Laboratory Tests", effective 11/25/2002 and implemented 01/01/2003. Multiple tumor markers are available for monitoring the response of certain malignancies to therapy and assessing whether residual tumor exists post-surgical therapy. As a laboratory NCD it carries a national ICD-10 edit list: 71 diagnosis codes support medical necessity and 245 are denied, applied automatically by every Medicare contractor to 1 procedure code.

Item or service described

Immunoassay determinations of the serum levels of certain proteins or carbohydrates serve as tumor markers. When elevated, serum concentration of these markers may reflect tumor size and grade. This policy specifically addresses the following tumor antigens: CA 15-3 and CA 27.29

Indications and limitations of coverage

Indications

Multiple tumor markers are available for monitoring the response of certain malignancies to therapy and assessing whether residual tumor exists post-surgical therapy.

CA 15-3 is often medically necessary to aid in the management of patients with breast cancer. Serial testing must be used in conjunction with other clinical methods for monitoring breast cancer. For monitoring, if medically necessary, use consistently either CA 15-3 or CA 27.29, not both.

CA 27.29 is equivalent to CA 15-3 in its usage in management of patients with breast cancer.

Limitations

These services are not covered for the evaluation of patients with signs or symptoms suggestive of malignancy. The service may be ordered at times necessary to assess either the presence of recurrent disease or the patient's response to treatment with subsequent treatment cycles.

Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).

Text reproduced from the CMS Medicare Coverage Database record for NCD 190.29 version 1. View the original on cms.gov.

Laboratory NCD code lists (January 2026)

Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The January 2026 list holds 71 covered and 245 non-covered ICD-10-CM codes plus 3 codes with other resolution rules.

1 procedure code are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.

Procedure codes subject to NCD 190.29
CodeCode set
86300CPT (descriptor licensed by AMA)

The first 40 of 71 covered diagnosis codes, with FY2027 ICD-10-CM descriptions. A claim with any covered code on the line supports medical necessity under the national edit.

Covered ICD-10-CM codes for NCD 190.29 (sample)
ICD-10-CMDescriptionEffective
C441321Sebaceous cell carcinoma of skin of right upper eyelid, including canthus2018-10-01
C441322Sebaceous cell carcinoma of skin of right lower eyelid, including canthus2018-10-01
C441391Sebaceous cell carcinoma of skin of left upper eyelid, including canthus2018-10-01
C441392Sebaceous cell carcinoma of skin of left lower eyelid, including canthus2018-10-01
C50011Malignant neoplasm of nipple and areola, right female breast2015-10-01
C50012Malignant neoplasm of nipple and areola, left female breast2015-10-01
C50019Malignant neoplasm of nipple and areola, unspecified female breast2015-10-01
C50021Malignant neoplasm of nipple and areola, right male breast2015-10-01
C50022Malignant neoplasm of nipple and areola, left male breast2015-10-01
C50029Malignant neoplasm of nipple and areola, unspecified male breast2015-10-01
C50111Malignant neoplasm of central portion of right female breast2015-10-01
C50112Malignant neoplasm of central portion of left female breast2015-10-01
C50119Malignant neoplasm of central portion of unspecified female breast2015-10-01
C50121Malignant neoplasm of central portion of right male breast2015-10-01
C50122Malignant neoplasm of central portion of left male breast2015-10-01
C50129Malignant neoplasm of central portion of unspecified male breast2015-10-01
C50211Malignant neoplasm of upper-inner quadrant of right female breast2015-10-01
C50212Malignant neoplasm of upper-inner quadrant of left female breast2015-10-01
C50219Malignant neoplasm of upper-inner quadrant of unspecified female breast2015-10-01
C50221Malignant neoplasm of upper-inner quadrant of right male breast2015-10-01
C50222Malignant neoplasm of upper-inner quadrant of left male breast2015-10-01
C50229Malignant neoplasm of upper-inner quadrant of unspecified male breast2015-10-01
C50311Malignant neoplasm of lower-inner quadrant of right female breast2015-10-01
C50312Malignant neoplasm of lower-inner quadrant of left female breast2015-10-01
C50319Malignant neoplasm of lower-inner quadrant of unspecified female breast2015-10-01
C50321Malignant neoplasm of lower-inner quadrant of right male breast2015-10-01
C50322Malignant neoplasm of lower-inner quadrant of left male breast2015-10-01
C50329Malignant neoplasm of lower-inner quadrant of unspecified male breast2015-10-01
C50411Malignant neoplasm of upper-outer quadrant of right female breast2015-10-01
C50412Malignant neoplasm of upper-outer quadrant of left female breast2015-10-01
C50419Malignant neoplasm of upper-outer quadrant of unspecified female breast2015-10-01
C50421Malignant neoplasm of upper-outer quadrant of right male breast2015-10-01
C50422Malignant neoplasm of upper-outer quadrant of left male breast2015-10-01
C50429Malignant neoplasm of upper-outer quadrant of unspecified male breast2015-10-01
C50511Malignant neoplasm of lower-outer quadrant of right female breast2015-10-01
C50512Malignant neoplasm of lower-outer quadrant of left female breast2015-10-01
C50519Malignant neoplasm of lower-outer quadrant of unspecified female breast2015-10-01
C50521Malignant neoplasm of lower-outer quadrant of right male breast2015-10-01
C50522Malignant neoplasm of lower-outer quadrant of left male breast2015-10-01
C50529Malignant neoplasm of lower-outer quadrant of unspecified male breast2015-10-01

245 diagnosis codes deny automatically under this NCD; the first 20 are shown.

Non-covered ICD-10-CM codes for NCD 190.29 (sample)
ICD-10-CMDescription
R99Ill-defined and unknown cause of mortality
Z0000Encounter for general adult medical examination without abnormal findings
Z0001Encounter for general adult medical examination with abnormal findings
Z00110Health examination for newborn under 8 days old
Z00111Health examination for newborn 8 to 28 days old
Z00121Encounter for routine child health examination with abnormal findings
Z00129Encounter for routine child health examination without abnormal findings
Z005Encounter for examination of potential donor of organ and tissue
Z006Encounter for examination for normal comparison and control in clinical research program
Z0070Encounter for examination for period of delayed growth in childhood without abnormal findings
Z0071Encounter for examination for period of delayed growth in childhood with abnormal findings
Z008Encounter for other general examination
Z020Encounter for examination for admission to educational institution
Z021Encounter for pre-employment examination
Z022Encounter for examination for admission to residential institution
Z023Encounter for examination for recruitment to armed forces
Z024Encounter for examination for driving license
Z025Encounter for examination for participation in sport
Z026Encounter for examination for insurance purposes
Z0271Encounter for disability determination

Revision history

07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)

07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

How QuickIntell applies NCD 190.29

QuickAuth checks the ordered service and diagnosis against NCD and LCD criteria before the encounter, QuickCode validates the diagnosis pairing on the claim, and QuickRCM routes CARC 50 denials with the policy text and the covered-code list attached so the appeal starts with evidence.

Frequently asked questions — NCD 190.29

What does NCD 190.29 cover?

Multiple tumor markers are available for monitoring the response of certain malignancies to therapy and assessing whether residual tumor exists post-surgical therapy. The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 190.29 take effect?

The current version (1) is effective 11/25/2002, implemented 01/01/2003, published in transmittal 17. This is the only published version.

Does a Local Coverage Determination override NCD 190.29?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Which diagnosis codes are covered under NCD 190.29?

The January 2026 laboratory NCD edit list contains 71 ICD-10-CM codes that support tumor antigen by immunoassay - ca 15-3/ca 27.29 (for example C441321 Sebaceous cell carcinoma of skin of right upper eyelid, including canthus; C441322 Sebaceous cell carcinoma of skin of right lower eyelid, including canthus; C441391 Sebaceous cell carcinoma of skin of left upper eyelid, including canthus) and 245 codes that deny. The list applies to 86300.

How often does the lab NCD code list for 190.29 change?

CMS updates the laboratory NCD edit module quarterly, with the January release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-02. Verify against the primary file before billing or contracting decisions.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.